17 Jan, EOD - Indian

SENSEX 76619.33 (-0.55)

Nifty 50 23203.2 (-0.47)

Nifty Bank 48540.6 (-1.50)

Nifty IT 42032.2 (-2.68)

Nifty Midcap 100 54607.65 (0.23)

Nifty Next 50 65053.6 (0.76)

Nifty Pharma 22061.7 (0.69)

Nifty Smallcap 100 17672.05 (0.16)

17 Jan, EOD - Global

NIKKEI 225 38451.46 (-0.31)

HANG SENG 19584.06 (0.31)

S&P 6044.5 (0.95)

Login/Signup
LOGIN HERE
Cancel

companylogoGland Pharma Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 543245 | NSE Symbol : GLAND | ISIN : INE068V01023 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
22-Oct-2024 04-Nov-2024 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Unaudited Financial results for the quarter and Half year ended September 30 2024 Appointment of Ms. Wei Huang as Additional Director w.e.f November 04, 2024 (As per BSE Announcement Dated on 04/11/2024)
19-Jul-2024 06-Aug-2024 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 inter alia to consider and approve Un-Audited Financial Results for the Quarter ended June 30 2024 Unaudited Financial Results for Q1 FY25 (As Per BSE Announcement dated on 06.08.2024)
07-Jun-2024 07-Jun-2024 Change in Directors Outcome of the Board Meeting held on June 07, 2024
09-May-2024 22-May-2024 Accounts Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Audited Financial Results for the quarter and financial year ended 31.03.2024 and to consider and recommend the payment of Final Dividend for FY 2023-24 Outcome of Board Meeting held on May 22, 2024 (As per BSE Announcement Dated on 22/05/2024)
29-Apr-2024 29-Apr-2024 Change in Other Executives Outcome of Board Meeting held on April 29, 2024 Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer
11-Jan-2024 14-Feb-2024 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Unaudited financial Results of the Company for the quarter and nine months ended December 31 2023 Unaudited Financial results for the quarter and nine months ended 31.12.2023 (As Per BSE Announcement Dated on: 14/02/2024)
17-Oct-2023 06-Nov-2023 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30th September 2023 The Board of Directors at its meeting held on November 06, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter and half year ended September 30, 2023 Unaudited financial results of the Company for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 06/11/2023)
27-Jul-2023 07-Aug-2023 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2023. The Board of Directors at its meeting held on August 07, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter ended June 30, 2023. Unaudited financial results of the Company for the quarter ended June 30, 2023 The Board has approved appointment of Mr. Prakash Vithal Baliga as Chief Operating Officer of the Company. (As Per BSE Announcement Dated on 07.08.2023)
28-Apr-2023 18-May-2023 Accounts Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2023 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2023. The Board of Directors at its meeting held on May 18, 2023 has inter-alia approved the Audited financial results of the Company for the quarter and financial year ended March 31, 2023. The 45th Annual General Meeting of the members of the Company will be held through video conferencing (VC)/ other audio-visual means (OAVM) on Thursday, August 31, 2023. Audited Financial Results for the quarter and year ended March 31, 2023 Revised outcome-The unsigned covering letter was filed inadvertently earlier. (As Per BSE Announcement dated on 18.05.2023)
29-Mar-2023 29-Mar-2023 Change in Auditors Recommendation for Appointment of Statutory Auditors of the Company
06-Jan-2023 23-Jan-2023 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2023 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2022 The Board of Directors at its meeting held on January 23, 2023 has inter-alia approved the Unaudited financial results of the Company for the quarter and nine months ended December 31, 2022. (As Per BSE Announcement dated on 23.01.2023) Newspaper Publication pertaining to Unaudited Financial Results of Q3FY23 (As Per BSE Announcement Dated on 24/01/2023)
10-Oct-2022 26-Oct-2022 Quarterly Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2022 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2022 The Board of Directors at its meeting held on October 26, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter and half year ended September 30, 2022. The Board of Directors at its meeting held on October 26, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter and half year ended September 30, 2022. (As Per BSE Announcement Dated on 26.10.2022)
04-Jul-2022 20-Jul-2022 Quarterly Results Quarterly Results The Board of Directors at its meeting held on July 20, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter ended June 30, 2022. (As Per BSE Announcement Dated on 20.07.2022)
04-Apr-2022 19-May-2022 Accounts Audited Results Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 ,inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31, 2022 The Board of Directors at its meeting held on May 19, 2022 has inter-alia approved the Audited financial results of the Company for the quarter and financial year ended March 31, 2022. The 44th Annual General Meeting of the members of the Company will be held through video conferencing (VC)/ other audio-visual means (OAVM) on Tuesday, August 30, 2022. Gland Pharma Ltd has informed BSE regarding Outcome of Board Meeting held on May 19, 2022. Audited Financial Results for the year ended March 31, 2022. (As per BSE Announcement Dated on 19/5/2022)
10-Mar-2022 10-Mar-2022 Change in Directors 1. Reappointment of Mr. Srinivas Sadu as MD & CEO for a period of 5 years w.e.f. 25th April, 2022, subject to the approval of the Members of the Company. 2. Appointment of Mr. Yao Fang as an Additional Director (Non-Independent and Non- Executive Director) 3. Resignation of Mr. Li Dongming as Director w.e.f. conclusion of the Board Meeting on March 10,2022
1 2 

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.
+91-22-25229720
+91-9769005430
>info@capitalmarket.com

For any Capital Market Website related queries mail to :
webdesk@capitalmarket.com

For Capital Market Magazine subscription queries :
+91-8657545825  

subscription@capitalmarket.com

For Capital Market Online Product related queries :
+91-8657545825  

financeshop@capitalmarket.com

To advertise on Capital Market Websites mail to :
advt@capitalmarket.com

To email Press Releases :
pressrelease@capitalmarket.com

Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages giving any kind of stock recommendations.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +